Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.37)
# 1,015
Out of 5,084 analysts
229
Total ratings
64.56%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $184.04 | +0.52% | 23 | Nov 11, 2025 | |
| CNC Centene | Maintains: Equal-Weight | $28 → $38 | $38.85 | -2.19% | 14 | Oct 14, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $325 → $395 | $333.49 | +18.44% | 20 | Sep 12, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $261.48 | +17.03% | 17 | Jul 25, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $71 → $60 | $51.31 | +16.94% | 10 | Apr 24, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.46 | +54.92% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.75 | +99.85% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $17.18 | -56.34% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $19.37 | -38.03% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $184.18 | -21.27% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $150.57 | +142.41% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $814.18 | -48.41% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $4.12 | +2,812.62% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $253.02 | +145.04% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $333.49 | +49.93% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $76.75 | +61.56% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $268.42 | +18.47% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $199.19 | -64.86% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $224.92 | -13.30% | 6 | Oct 21, 2020 |
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $184.04
Upside: +0.52%
Centene
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $28 → $38
Current: $38.85
Upside: -2.19%
UnitedHealth Group
Sep 12, 2025
Maintains: Overweight
Price Target: $325 → $395
Current: $333.49
Upside: +18.44%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $261.48
Upside: +17.03%
Doximity
Apr 24, 2025
Maintains: Equal-Weight
Price Target: $71 → $60
Current: $51.31
Upside: +16.94%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.46
Upside: +54.92%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.75
Upside: +99.85%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $17.18
Upside: -56.34%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $19.37
Upside: -38.03%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $184.18
Upside: -21.27%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $150.57
Upside: +142.41%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $814.18
Upside: -48.41%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $4.12
Upside: +2,812.62%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $253.02
Upside: +145.04%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $333.49
Upside: +49.93%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $76.75
Upside: +61.56%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $268.42
Upside: +18.47%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $199.19
Upside: -64.86%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $224.92
Upside: -13.30%